Evidenzbasierte Empfehlungen zur Primärbehandlung von Mammakarzinomen

Die Organkommission 1Mammaa der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) hat sich die Erarbeitung von Empfehlungen zur Therapie von Mammakarzinomen zur Aufgabe gemacht. Zielsetzung war die Definition des aktuellen evidenzbasierten Wissensstandes zur Primärtherapie dieser Erkrankung. Zu aktuellen Aspekten wurden Kernaussagen formuliert und nach zweierlei Gesichtspunkten bewertet: ± Festlegung des Evidenzniveaus (Level of Evidence, LOE) nach Sichtung der aktuellen Literatur und Bewertung der verfügbaren Datenqualität. ± Festlegung des Empfehlungsgrades entsprechend der Konsistenz der Ergebnisse verschiedener Untersuchungen und des klinischen Stellenwertes.

[1]  M. Clarke.  WITHDRAWN: Ovarian ablation for early breast cancer. , 2008, The Cochrane database of systematic reviews.

[2]  J. Tobias.  The ATAC ('Arimidex', tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal (PM) women , 2002 .

[3]  I. Barillot,et al.  Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. , 2001, The New England journal of medicine.

[4]  M. Press,et al.  Improved survival benefit from Herceptin (trastuzumab) and chemotherapy in patients selected by fluorescence in situ hybridization. , 2001 .

[5]  M. Kaufmann,et al.  The emerging role of hormonal ablation as adjuvant therapy in node + and node – pre-/perimenopausal patients , 2001 .

[6]  L Duchateau,et al.  Risk factors for recurrence and metastasis after breast-conserving therapy for ductal carcinoma-in-situ: analysis of European Organization for Research and Treatment of Cancer Trial 10853. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  S. Edge,et al.  Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Eusoma.  The requirements of a specialist breast unit. , 2000, European journal of cancer.

[9]  E. Vandeweyer,et al.  Radiation Therapy after Immediate Breast Reconstruction with Implants , 2000, Plastic and reconstructive surgery.

[10]  B. Cady.  A contemporary view of axillary dissection. , 2000, Annals of surgery.

[11]  G. Soete,et al.  Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  L Collette,et al.  The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. , 2000, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[13]  B. Hillner,et al.  American Society of Clinical Oncology Guideline on the Role of Bisphosphonates in Breast Cancer , 2000 .

[14]  A. Recht.  Should irradiation replace dissection for patients with breast cancer with clinically negative axillary lymph nodes? , 1999, Journal of surgical oncology.

[15]  D. Wickerham,et al.  Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  G. Noël,et al.  [Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: findings from national surgical adjuvant breast and bowel project B-17]. , 1999, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[17]  G. Noël,et al.  [Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomized controlled trial]. , 1999, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[18]  J. Baselga.  Safety profile of Herceptin (R) as a single agent and in combination with chemotherapy , 1999 .

[19]  G. Robb,et al.  Local recurrence risk after skin-sparing and conventional mastectomy: a 6-year follow-up. , 1999, Plastic and reconstructive surgery.

[20]  S. Martino,et al.  The influence of margin width on local control of ductal carcinoma in situ of the breast. , 1999, The New England journal of medicine.

[21]  R. Samant,et al.  Staging investigations in patients with breast cancer: the role of bone scans and liver imaging. , 1999, Archives of surgery.

[22]  M. Sliwkowski,et al.  Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers , 1999, Oncogene.

[23]  M. Somerfield,et al.  Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  D. L. Berry,et al.  Management of breast cancer during pregnancy using a standardized protocol. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  Mike Clarke,et al.  Polychemotherapy for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[26]  D. Wallwiener,et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.

[27]  D. Tu,et al.  Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Tavassoli,et al.  Mammary ductal carcinoma in Situ with microinvasion , 1998, Cancer.

[29]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[30]  J. Wagstaff,et al.  Management of Stage III Breast Cancer , 1998, Oncology.

[31]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  A. Hanlon,et al.  Identification of women with T1‐T2 breast cancer at low risk of positive axillary nodes , 1997, Journal of surgical oncology.

[33]  N. O’higgins,et al.  Principles and guidelines for surgeons--management of symptomatic breast cancer. European Society of Surgical Oncology. , 1997, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[34]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[35]  M. Cunningham,et al.  Factors affecting outcome of patients with impalpable breast cancer detected by breast screening , 1996, The British journal of surgery.

[36]  A. Recht,et al.  The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. , 1996, The New England journal of medicine.

[37]  K. Kerlikowske,et al.  Incidence of and treatment for ductal carcinoma in situ of the breast. , 1996, JAMA.

[38]  J. Gazet,et al.  The importance of the resection margin in conservative surgery for breast cancer. , 1996, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[39]  W. Dupont,et al.  Continued local recurrence of carcinoma 15–25 years after a diagnosis of low grade ductal carcinoma in situ of the breast treated only by biopsy , 1995, Cancer.

[40]  M. J. Silverstein,et al.  Prognostic classification of breast ductal carcinoma-in-situ , 1995, The Lancet.

[41]  G. Bonadonna,et al.  Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. , 1995, The New England journal of medicine.

[42]  D. Talbot,et al.  Carboplatin in the treatment of advanced breast cancer: a phase II study using a pharmacokinetically guided dose schedule. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Nooij,et al.  "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer. An EORTC Breast Cancer Co-operative Group Phase III Trial (10808). , 1991, European journal of cancer.

[44]  G. Sledge,et al.  Cisplatin as first-line therapy for metastatic breast cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  F. Hamdy,et al.  THE NEW ENGLAND JOURNAL OF MEDICINE , 1962, The Lancet.

[46]  B. Fisher,et al.  Conservative surgery for the management of invasive and noninvasive carcinoma of the breast: NSABP trials , 2004, World Journal of Surgery.

[47]  N. Perry.  Quality assurance in the diagnosis of breast disease. EUSOMA Working Party. , 2001, European journal of cancer.

[48]  C. Blomqvist,et al.  Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  G Noël,et al.  [Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials]. , 2001, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

[50]  B. Hillner,et al.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. Rezai,et al.  Tumor-Specific Immediate Reconstruction in Breast Cancer Patients , 1998 .

[52]  N. O’higgins,et al.  Principles and guidelines for surgeonsmanagement of symptomatic breast cancer , 1997 .

[53]  T. Landberg,et al.  The total incidence of loco-regional recurrence in a randomized trial of breast cancer TNM stage II. The South Sweden Breast Cancer Trial. , 1993, Acta oncologica.